H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 114 Citations 66,010 558 World Ranking 2045 National Ranking 1194

Research.com Recognitions

Awards & Achievements

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

John M. Kirkwood mainly focuses on Melanoma, Internal medicine, Oncology, Surgery and Immunology. His Melanoma research includes themes of Cancer, Adjuvant therapy, Pathology, Stage and Survival analysis. His work is dedicated to discovering how Oncology, Alpha interferon are connected with Prospective cohort study and other disciplines.

His Surgery study integrates concerns from other disciplines, such as Gastroenterology and Metastasis. As a member of one scientific family, John M. Kirkwood mostly works in the field of Immunology, focusing on Cytotoxic T cell and, on occasion, T cell, Epitope, CD8 and Cancer research. His research investigates the connection between Dacarbazine and topics such as Vemurafenib that intersect with issues in V600E.

His most cited work include:

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
  • Final Version of 2009 AJCC Melanoma Staging and Classification (3479 citations)
  • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. (1741 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Melanoma, Internal medicine, Oncology, Immunology and Cancer research. His Melanoma study combines topics in areas such as Cancer, Immunotherapy, Pathology, Alpha interferon and Stage. His studies in Internal medicine integrate themes in fields like Gastroenterology and Surgery.

The Oncology study which covers Chemotherapy that intersects with Toxicity. While the research belongs to areas of Immunology, he spends his time largely on the problem of Cytotoxic T cell, intersecting his research to questions surrounding Epitope. His Cancer research research includes elements of Cell and Cytokine.

He most often published in these fields:

  • Melanoma (61.75%)
  • Internal medicine (45.99%)
  • Oncology (35.77%)

What were the highlights of his more recent work (between 2015-2021)?

  • Melanoma (61.75%)
  • Internal medicine (45.99%)
  • Oncology (35.77%)

In recent papers he was focusing on the following fields of study:

Melanoma, Internal medicine, Oncology, Cancer research and Immunotherapy are his primary areas of study. The study incorporates disciplines such as Cancer, Clinical trial, Surgery, Adverse effect and Immune system in addition to Melanoma. His work on Adjuvant, Ipilimumab, Pembrolizumab and Dabrafenib as part of general Internal medicine study is frequently linked to In patient, therefore connecting diverse disciplines of science.

His work carried out in the field of Ipilimumab brings together such families of science as Interferon alfa, Nivolumab and Randomized controlled trial. His Oncology study incorporates themes from Advanced melanoma, Survival rate, Trametinib, Stage and Adjuvant therapy. His work focuses on many connections between Cancer research and other disciplines, such as T cell, that overlap with his field of interest in Immune checkpoint.

Between 2015 and 2021, his most popular works were:

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. (793 citations)
  • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (611 citations)
  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma (594 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His primary areas of investigation include Melanoma, Internal medicine, Cancer research, Oncology and Immunotherapy. His Melanoma research integrates issues from Cancer, Surgery, T cell, Immunology and Cancer immunotherapy. Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Gastroenterology.

The various areas that John M. Kirkwood examines in his Cancer research study include Microvesicles, Cell, Anti pd 1 and CD8. His biological study spans a wide range of topics, including Pembrolizumab, Dabrafenib, Gene mutation, Hazard ratio and Biomarker. In his work, Talimogene laherparepvec is strongly intertwined with Oncolytic virus, which is a subfield of Immunotherapy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen.
The New England Journal of Medicine (2011)

7772 Citations

Final Version of 2009 AJCC Melanoma Staging and Classification

Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson.
Journal of Clinical Oncology (2009)

4876 Citations

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

John M. Kirkwood;Myla Hunt Strawderman;Marc S. Ernstoff;Thomas J. Smith.
Journal of Clinical Oncology (1996)

2565 Citations

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf.
Lancet Oncology (2015)

1325 Citations

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

John M. Kirkwood;Joseph G. Ibrahim;Jeffrey A. Sosman;Vernon K. Sondak.
Journal of Clinical Oncology (2001)

1217 Citations

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

John M. Kirkwood;Joseph G. Ibrahim;Vernon K. Sondak;Jon Richards.
Journal of Clinical Oncology (2000)

1077 Citations

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak.
CA: A Cancer Journal for Clinicians (2017)

1076 Citations

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin.
Lancet Oncology (2014)

984 Citations

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

Julien Fourcade;Zhaojun Sun;Mourad Benallaoua;Philippe Guillaume.
Journal of Experimental Medicine (2010)

961 Citations

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

G. V. Long;A. Hauschild;M. Santinami;V. Atkinson.
The New England Journal of Medicine (2017)

857 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing John M. Kirkwood

Richard A. Scolyer

Richard A. Scolyer

Royal Prince Alfred Hospital

Publications: 317

John F. Thompson

John F. Thompson

University of Sydney

Publications: 304

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 283

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 248

Claus Garbe

Claus Garbe

University of Tübingen

Publications: 215

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 209

Reinhard Dummer

Reinhard Dummer

University of Zurich

Publications: 197

Alexander M.M. Eggermont

Alexander M.M. Eggermont

Erasmus University Rotterdam

Publications: 196

Caroline Robert

Caroline Robert

Institut Gustave Roussy

Publications: 175

Keith T. Flaherty

Keith T. Flaherty

Harvard University

Publications: 171

Jedd D. Wolchok

Jedd D. Wolchok

Memorial Sloan Kettering Cancer Center

Publications: 162

Antoni Ribas

Antoni Ribas

University of California, Los Angeles

Publications: 155

Vernon K. Sondak

Vernon K. Sondak

University of South Florida

Publications: 148

Richard F. Kefford

Richard F. Kefford

Macquarie University

Publications: 148

Axel Hauschild

Axel Hauschild

Kiel University

Publications: 138

Alexander M. Menzies

Alexander M. Menzies

University of Sydney

Publications: 137

Something went wrong. Please try again later.